Berhane CC, Brantley K, Williams S, Sutton E, Kappy C, et al.
Journal of wound care. Date of publication 2019 May 1;volume 28(Sup5):S4-S10.
1. J Wound Care. 2019 May 1;28(Sup5):S4-S10. doi: 10.12968/jowc.2019.28.Sup5.S4.
An evaluation of dehydrated human amnion/chorion membrane allografts for
pressure ulcer treatment: a case series.
Berhane CC(1), Brantley K(1), Williams S(1), Sutton E(1), Kappy C(1).
Author information:
(1)Department of Reconstructive Surgery, Shepherd Center, Atlanta, GA, US.
OBJECTIVE: Pressure ulcers (PU; also known as pressure injuries) affect about
three million adults in the US and cost an estimated $11 billion dollars
annually to treat. Prevention is most desirable, however, once a patient
develops a PU, the focus shifts to effective treatment and rapid closure to
improve health outcomes. We sought to evaluate outcomes in 10 patients with
category II and III PUs treated with dehydrated human amnion/chorion membrane
(dHACM) allografts.
METHOD: All patients were treated with weekly application of dHACM plus standard
wound care (SoC) and followed for eight weeks.
RESULTS: Of the PUs, two were category II and eight were category III. The
average PU size at dHACM initiation was 3.42±1.76cm2. After the first
application of dHACM 7/10 (70%) of PUs responded to treatment with a reduction
in wound size. Within two weeks of dHACM initiation into the plan of care, 4/10
(40%) of PUs had reduced in size by >50%. By week four, 60% of PUs (6/10) had
reduced in size by >50%. Overall, during the eight week evaluation period, 9/10
PUs reduced in size, three of which healed completely.
CONCLUSION: dHACM allografts appear to be a viable treatment option for category
II and III PUs.
DOI: 10.12968/jowc.2019.28.Sup5.S4
PMID: 31067170 [Indexed for MEDLINE]
Appears in following Topics:
